STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.

Authors

Delvys Rodriguez-Abreu

Complejo HU de Canarias, Santa Cruz De Tenerife, Spain

Delvys Rodriguez-Abreu , Jhanelle Elaine Gray , Myung-Ju Ahn , Melissa Lynne Johnson , Xinwei Yu , Xueying Chen , Patrick Hoang Phuong , Jongseok Kim , Martin Reck

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.

First Author: Marina Chiara Garassino

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.

First Author: Christos Chouaid

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC).

First Author: Alexander I. Spira

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).

First Author: Mustafa Özgüroğlu